$6.03 Billion in Sales Expected for Novo Nordisk A/S (NYSE:NVO) This Quarter

Wall Street brokerages expect that Novo Nordisk A/S (NYSE:NVOGet Rating) will report $6.03 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Novo Nordisk A/S’s earnings. The highest sales estimate is $6.05 billion and the lowest is $6.02 billion. Novo Nordisk A/S posted sales of $5.35 billion during the same quarter last year, which suggests a positive year over year growth rate of 12.7%. The company is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Novo Nordisk A/S will report full-year sales of $24.44 billion for the current fiscal year, with estimates ranging from $24.11 billion to $24.75 billion. For the next year, analysts anticipate that the company will report sales of $27.25 billion, with estimates ranging from $26.86 billion to $27.45 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVOGet Rating) last released its quarterly earnings results on Friday, April 29th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.85 by $0.09. The business had revenue of $6.34 billion during the quarter, compared to analyst estimates of $5.82 billion. Novo Nordisk A/S had a net margin of 33.16% and a return on equity of 72.67%.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $104.00 price objective on the stock in a report on Friday, February 25th. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, March 2nd. Barclays increased their price target on shares of Novo Nordisk A/S from 750.00 to 850.00 in a report on Thursday, April 14th. StockNews.com assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Finally, Danske upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $559.33.

NVO stock opened at $107.44 on Wednesday. The firm has a market cap of $253.00 billion, a price-to-earnings ratio of 31.98, a PEG ratio of 2.29 and a beta of 0.47. The firm has a 50-day simple moving average of $111.05 and a two-hundred day simple moving average of $107.82. Novo Nordisk A/S has a one year low of $75.44 and a one year high of $122.16. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.66 and a current ratio of 0.91.

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 5th. Stockholders of record on Monday, March 28th were given a dividend of $0.741 per share. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. The ex-dividend date was Friday, March 25th. This represents a dividend yield of 1.1%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 44.05%.

Large investors have recently made changes to their positions in the company. Ahrens Investment Partners LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $25,000. Farmers & Merchants Investments Inc. purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $26,000. Bell Investment Advisors Inc purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Cornerstone Advisory LLC purchased a new position in Novo Nordisk A/S in the 4th quarter valued at $28,000. Finally, Fortis Advisors LLC purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at $29,000.

Novo Nordisk A/S Company Profile (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.